Jacobs Levy Equity Management
TGTX icon

Jacobs Levy Equity Management’s TG Therapeutics TGTX Stock Holding History

Jacobs Levy Equity Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-85,849
Closed -$3.39M – 1162
2025
Q1 		$3.39M Buy
85,849
+1,260
+1% +$42.4K 0.01% 550
2024
Q4 		$2.55M Sell
84,589
-95,749
-53% -$2.75M 0.01% 550
2024
Q3 		$4.22M Hold
180,338
– – 0.02% 468
2024
Q2 		$3.21M Sell
180,338
-344,523
-66% -$5.5M 0.01% 514
2024
Q1 		$7.98M Buy
524,861
+120,699
+30% +$1.92M 0.04% 337
2023
Q4 		$6.9M Sell
404,162
-1,456
-0.4% -$16.9K 0.03% 364
2023
Q3 		$3.39M Buy
405,618
+145,667
+56% +$2.03M 0.02% 451
2023
Q2 		$6.46M Hold
259,951
– – 0.04% 340
2023
Q1 		$3.91M Sell
259,951
-107,522
-29% -$1.63M 0.02% 454
2022
Q4 		$4.35M Buy
367,473
+254,978
+227% +$1.85M 0.03% 420
2022
Q3 		$666K Buy
+112,495
New +$738K 0.01% 787
2020
Q3 		– Sell
-23,900
Closed -$466K – 1107
2020
Q2 		$466K Sell
23,900
-1,501
-6% -$24.2K 0.01% 801
2020
Q1 		$250K Sell
25,401
-143,799
-85% -$1.82M ﹤0.01% 848
2019
Q4 		$1.88M Buy
169,200
+48,800
+41% +$371K 0.02% 557
2019
Q3 		$676K Buy
120,400
+12,400
+11% +$86.4K 0.01% 672
2019
Q2 		$934K Buy
+108,000
New +$816K 0.01% 653
2018
Q3 		– Sell
-26,710
Closed -$351K – 1071
2018
Q2 		$351K Buy
+26,710
New +$367K 0.01% 869

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Jacobs Levy Equity Management's TGTX Position: Q2 2025 in Review

Jacobs Levy Equity Management sold out of TG Therapeutics (TGTX) in Q2 2025, closing a stake of 85,849 shares — an estimated $3.39M sold.

Jacobs Levy Equity Management first reported a position in TGTX in Q2 2018 and held it in 17 quarters. The position peaked at $7.98M in Q1 2024. 356 funds tracked by Wall St. Rank hold TGTX as of Q2 2025.

  • Jacobs Levy Equity Management reported no remaining TG Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 85,849 TG Therapeutics shares in Q2 2025, an estimated $3.39M.
  • Jacobs Levy Equity Management first reported a position in TG Therapeutics in Q2 2018 and held it in 17 quarters.
  • Jacobs Levy Equity Management's TG Therapeutics position peaked at $7.98M in Q1 2024.
  • 356 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q2 2025, filed 14 Aug 2025.